Physician profile
David E Smith
NPI 1912903741
$1,365.37
in general payments reported to CMS, 2019-2025
24 companies · $457 in 2025
The $457 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $22.95 · 2021: $26.33 · 2022: $48.98 · 2023: $127 · 2024: $536 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,119.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $166.19 | 2023-2024 | Vraylar |
| Lilly USA, LLC | $143.62 | 2019-2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $133.30 | 2024-2025 | |
| Gilead Sciences, INC. | $121.25 | 2022-2025 | Epclusa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.21 | 2019-2024 | Xifaxan |
| Aimmune Therapeutics, INC. | $109.81 | 2024-2025 | Zenpep |
| Axsome Therapeutics, INC. | $78.06 | 2024-2025 | Auvelity |
| Novo Nordisk INC | $56.10 | 2019-2025 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $51.96 | 2025 | |
| Glaxosmithkline, LLC. | $50.42 | 2019-2024 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals Lp | $50.09 | 2024-2025 | Farxiga, Airsupra |
| Amgen INC. | $35.29 | 2023-2024 | Repatha, Otezla |
| Pfizer INC. | $29.91 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $26.67 | 2019-2025 | Spravato |
| Dexcom, INC. | $26.38 | 2025 | Dexcom G6 Transmitter |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $24.09 | 2025 | Cobenfy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.82 | 2025 | Jardiance |
| Tonix Medicines, INC. | $21.36 | 2025 | Tonmya |
| Astellas Pharma US INC | $21.03 | 2025 | Veozah |
| Paratek Pharmaceuticals, INC. | $18.63 | 2025 | Nuzyra, Xhance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.49 | 2024 | Caplyta |
| Insulet Corporation | $17.11 | 2024 | Omnipod |
| Phathom Pharmaceuticals, INC. | $15.39 | 2025 | Voquezna |
| Exact Sciences Corporation | $15.19 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.